45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
94,744
Insurances with rates
25
CPT / HCPCS codes
0
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| 109228707-2255394 | 00310-4535-30 - tremelimumab actl 20 mg/mL Soln | $1,294,935 | $466,176 | — | — | 8 |
| 109228707-2255394 | 00310-4535-30 - tremelimumab actl 20 mg/mL Soln | $1,294,935 | $388,480 | — | — | 13 |
| 108290516-2255394 | 72187-0401-01 - tagraxofusp 1000 mcg/mL Soln | $1,027,847 | $370,025 | — | — | 8 |
| 108290516-2255394 | 72187-0401-01 - tagraxofusp 1000 mcg/mL Soln | $1,027,847 | $308,354 | — | — | 13 |
| 108290269-2255394 | 79952-0110-01 - loncastuximab tesirine 10 mg Injec | $874,475 | $314,811 | — | — | 8 |
| 108290269-2255394 | 79952-0110-01 - loncastuximab tesirine 10 mg Injec | $874,475 | $262,343 | — | — | 13 |
| 1287035-2255394 | 76128-0155-75 - porfimer 75. mg REC Injection | $815,037 | $293,413 | — | — | 8 |
| 1287035-2255394 | 76128-0155-75 - porfimer 75. mg REC Injection | $815,037 | $244,511 | — | — | 27 |
| 108503656-2255394 | 72493-0103-03 - mitoMYcin 40 mg Kit | $787,028 | $283,330 | — | — | 8 |
| 108503656-2255394 | 72493-0103-03 - mitoMYcin 40 mg Kit | $787,028 | $236,108 | — | — | 13 |
| 108819334-2255394 | 00008-0100-01 - inotuzumab ozogamicin 0.9 mg Powde | $738,295 | $265,786 | — | — | 8 |
| 108819334-2255394 | 00008-0100-01 - inotuzumab ozogamicin 0.9 mg Powde | $738,295 | $221,488 | — | — | 13 |
| 108087544-2255393 | 67979-0002-01 - histrelin 50 mg Implan | $706,155 | $254,216 | — | — | 8 |
| 108087544-2255393 | 67979-0002-01 - histrelin 50 mg Implan | $706,155 | $211,847 | — | — | 13 |
| 108963946-2255393 | 69866-1025-01 - autologous cultured chondrocytes 0 | $680,870 | $245,113 | — | — | 8 |
| 108963946-2255393 | 69866-1025-01 - autologous cultured chondrocytes 0 | $680,870 | $204,261 | — | — | 13 |
| 108963947-2255393 | 69866-1030-05 - autologous cultured chondrocytes i | $680,870 | $245,113 | — | — | 8 |
| 108963947-2255393 | 69866-1030-05 - autologous cultured chondrocytes i | $680,870 | $204,261 | — | — | 13 |
| 108978003-2255393 | 69866-1030-08 - autologous cultured chondrocytes 1 | $680,870 | $245,113 | — | — | 8 |
| 108978003-2255393 | 69866-1030-08 - autologous cultured chondrocytes 1 | $680,870 | $204,261 | — | — | 13 |
| 108031526-2255394 | 50242-0105-01 - polatuzumab vedotin 140 mg Powder | $582,489 | $209,696 | — | — | 8 |
| 108031526-2255394 | 50242-0105-01 - polatuzumab vedotin 140 mg Powder | $582,489 | $174,747 | — | — | 13 |
| 108329173-2255396 | 71336-1001-01 - givosiran 189 mg/mL Soln | $542,100 | $195,156 | — | — | 8 |
| 108329173-2255396 | 71336-1001-01 - givosiran 189 mg/mL Soln | $542,100 | $162,630 | — | — | 13 |
| 108815520-2255394 | 00003-7125-11 - nivolumab-relatlimab rmbw 240 mg-8 | $482,528 | $173,710 | — | — | 8 |
| 108815520-2255394 | 00003-7125-11 - nivolumab-relatlimab rmbw 240 mg-8 | $482,528 | $144,758 | — | — | 13 |
| 1279402-2255396 | 00003-2328-22 - ipilimumab Soln | $473,741 | $170,547 | — | — | 8 |
| 1279402-2255396 | 00003-2328-22 - ipilimumab Soln | $473,741 | $142,122 | — | — | 13 |
| 1284898-2255394 | 48818-0001-02 - PRALAtrexate Soln | $468,317 | $168,594 | — | — | 8 |
| 1284898-2255394 | 48818-0001-02 - PRALAtrexate Soln | $468,317 | $140,495 | — | — | 13 |
| 1288090-2255394 | 00024-5824-11 - cabazitaxel Soln | $460,504 | $165,781 | — | — | 8 |
| 1288090-2255394 | 00024-5824-11 - cabazitaxel Soln | $460,504 | $138,151 | — | — | 14 |
| 108927364-2255394 | 50242-0245-01 - pertuzumab-trastuz-hyaluron-zzxf 1 | $434,574 | $156,447 | — | — | 8 |
| 108927364-2255394 | 50242-0245-01 - pertuzumab-trastuz-hyaluron-zzxf 1 | $434,574 | $130,372 | — | — | 13 |
| 102537516-2255394 | 66302-0014-01 - dinutuximab 17.5 mg/5 mL Soln | $393,554 | $141,679 | — | — | 8 |
| 102537516-2255394 | 66302-0014-01 - dinutuximab 17.5 mg/5 mL Soln | $393,554 | $118,066 | — | — | 13 |
| 104437516-2255396 | 75987-0080-10 - pegloticase 8 mg/mL Soln | $388,108 | $139,719 | — | — | 8 |
| 104437516-2255396 | 75987-0080-10 - pegloticase 8 mg/mL Soln | $388,108 | $116,432 | — | — | 13 |
| 1286149-2255396 | 54396-0801-01 - pegloticase Soln | $388,108 | $139,719 | — | — | 8 |
| 1286149-2255396 | 54396-0801-01 - pegloticase Soln | $388,108 | $116,432 | — | — | 13 |
| 109148167-2255394 | 00173-0898-03 - dostarlimab gxly 500 mg/10 mL Soln | $376,407 | $135,507 | — | — | 8 |
| 109148167-2255394 | 00173-0898-03 - dostarlimab gxly 500 mg/10 mL Soln | $376,407 | $112,922 | — | — | 13 |
| 1278993-2255394 | 51144-0050-01 - brentuximab vedotin REC Injection | $375,792 | $135,285 | — | — | 8 |
| 1278993-2255394 | 51144-0050-01 - brentuximab vedotin REC Injection | $375,792 | $112,737 | — | — | 13 |
| 108107889-2255396 | 72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5 | $354,982 | $127,793 | — | — | 8 |
| 108107889-2255396 | 72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5 | $354,982 | $106,494 | — | — | 13 |
| 1282361-2255396 | 57665-0002-02 - pegaspargase 3750. Soln | $354,982 | $127,793 | — | — | 8 |
| 1282361-2255396 | 57665-0002-02 - pegaspargase 3750. Soln | $354,982 | $106,494 | — | — | 13 |
| 1282362-2255396 | 54482-0301-01 - pegaspargase 3750. Soln | $354,982 | $127,793 | — | — | 8 |
| 1282362-2255396 | 54482-0301-01 - pegaspargase 3750. Soln | $354,982 | $106,494 | — | — | 13 |
Showing top 50 of 94,744 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.